Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mitocholine Ltd. is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is spread across 3 distinct examiners and a matching number of art units, indicating that each pending matter is being treated as a unique technical and legal entity. CLARK, AMY LYNN is the busiest examiner, responsible for 1 pending action.
The use of those art units for only the 3 pending office actions suggests that Mitocholine Ltd. is pursuing diverse applications within the Biotechnology & Pharmaceuticals field. Since each action is assigned to a distinct examiner, there is no centralization of examiner authority. This distribution requires the applicant to tailor their responses to the specific requirements of different units.
With the matters and those examiners, the company avoids the risk of a single examiner bottleneck. However, the lack of overlap across the units means that prosecution insights gained in one matter may have limited applicability to the others. Practitioners should focus on the individual nuances of each of the matters. CLARK, AMY LYNN oversees 1 pending action, providing one of the unique perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.1% | +31.2% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685328 | NUTRITIONAL COMPOSITIONS | CLARK, AMY LYNN | — |
| 18394525 | NUTRITIONAL COMPOSITIONS FOR SKELETAL MUSCLE | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685328 | NUTRITIONAL COMPOSITIONS | CLARK, AMY LYNN | — |
| 18394525 | NUTRITIONAL COMPOSITIONS FOR SKELETAL MUSCLE | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685328 | NUTRITIONAL COMPOSITIONS | CLARK, AMY LYNN | 1628 | §102§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18394525 | NUTRITIONAL COMPOSITIONS FOR SKELETAL MUSCLE | SZNAIDMAN, MARCOS L | 1623 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18566415 | NUTRITIONAL COMPOSITIONS FOR SKELETAL MUSCLE | KRISHNAN, GANAPATHY | 1693 | §103§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial